On the public citation graph

Resistance profiles of anaplastic lymphoma kinase tyrosine kinase inhibitors in advanced non–small-cell lung cancer: a multicenter study using targeted next-generation sequencing

https://doi.org/10.1016/j.ejca.2021.06.043

0 signed · 79 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/j.annonc.2020.04.478openalex-snapshot

Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study

inferredcites →https://doi.org/10.1016/j.ccell.2018.06.006openalex-snapshot

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development

inferredcites →https://doi.org/10.1016/j.ccr.2011.04.004openalex-snapshot

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

inferredcites →https://doi.org/10.1016/j.cllc.2016.03.005openalex-snapshot

Anaplastic Lymphoma Kinase (ALK) Kinase Domain Mutation Following ALK Inhibitor(s) Failure in Advanced ALK Positive Non–Small-Cell Lung Cancer: Analysis and Literature Review

inferredcites →https://doi.org/10.1016/j.cllc.2017.04.013openalex-snapshot

Detection of ALK and KRAS Mutations in Circulating Tumor DNA of Patients With Advanced ALK-Positive NSCLC With Disease Progression During Crizotinib Treatment

inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

inferredcites →https://doi.org/10.1016/j.jtho.2016.11.2231openalex-snapshot

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib

inferredcites →https://doi.org/10.1016/j.jtho.2019.08.003openalex-snapshot

Monitoring Therapeutic Response and Resistance: Analysis of Circulating Tumor DNA in Patients With ALK+ Lung Cancer

inferredcites →https://doi.org/10.1016/j.jtho.2020.04.019openalex-snapshot

An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor–Refractory ALK-Positive or ROS1-Positive NSCLC

inferredcites →https://doi.org/10.1016/j.lungcan.2018.07.004openalex-snapshot

Next generation sequencing reveals a novel ALK G1128A mutation resistant to crizotinib in an ALK-Rearranged NSCLC patient

inferredcites →https://doi.org/10.1016/s0140-6736(17)30123-xopenalex-snapshot

First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

inferredcites →https://doi.org/10.1038/srep35249openalex-snapshot

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition

inferredcites →https://doi.org/10.1056/nejmc1410799openalex-snapshot

Novel Mutations in a Patient with ALK-Rearranged Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1007478openalex-snapshot

EML4-ALK Mutations in Lung Cancer That Confer Resistance to ALK Inhibitors

inferredcites →https://doi.org/10.1056/nejmoa1408440openalex-snapshot

First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa1810171openalex-snapshot

Brigatinib versus Crizotinib in ALK -Positive Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1056/nejmoa2027187openalex-snapshot

First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer

inferredcites →https://doi.org/10.1080/15384047.2018.1433496openalex-snapshot

Capture-based ultra-deep sequencing in plasma ctDNA reveals the resistance mechanism of ALK inhibitors in a patient with advanced ALK-positive NSCLC

inferredcites →https://doi.org/10.1093/annonc/mdr626openalex-snapshot

Activating c-KIT mutations in a subset of thymic carcinoma and response to different c-KIT inhibitors

inferredcites →https://doi.org/10.1097/jto.0000000000000358openalex-snapshot

Secondary Mutations at I1171 in the ALK Gene Confer Resistance to Both Crizotinib and Alectinib

inferredcites →https://doi.org/10.1097/jto.0b013e318283dcc0openalex-snapshot

Heterogeneity of Genetic Changes Associated with Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancer

inferredcites →https://doi.org/10.1126/scitranslmed.3003316openalex-snapshot

Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-1648openalex-snapshot

ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

inferredcites →https://doi.org/10.1158/1078-0432.ccr-11-2906openalex-snapshot

Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-3173openalex-snapshot

Characteristics of Lung Cancers Harboring NRAS Mutations

inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0318openalex-snapshot

ALK Rearrangements Are Mutually Exclusive with Mutations in EGFR or KRAS : An Analysis of 1,683 Patients with Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-16-3273openalex-snapshot

Acquired MET Y1248H and D1246N Mutations Mediate Resistance to MET Inhibitors in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-2588openalex-snapshot

Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer

inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-1104openalex-snapshot

Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer

inferredcites →https://doi.org/10.1158/2159-8290.cd-16-0596openalex-snapshot

Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK -Rearranged Lung Cancer

inferredcites →https://doi.org/10.1158/2159-8290.cd-17-1256openalex-snapshot

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive Lung Cancer

inferredcites →https://doi.org/10.1200/jco.18.02236openalex-snapshot

ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.9030openalex-snapshot

Acquired resistance to MET inhibition in MET driven NSCLC.

inferredcites →https://doi.org/10.1200/jco.2019.37.15_suppl.e20532openalex-snapshot

EGFR extracellular domain mutation in patients with lung cancer.

inferredcites →https://doi.org/10.18632/oncotarget.2834openalex-snapshot

PIK3CA mutations in non-small cell lung cancer (NSCLC): Genetic heterogeneity, prognostic impact and incidence of prior malignancies

inferredcites →https://doi.org/10.3389/fonc.2019.01088openalex-snapshot

A Comparative Analysis of Individual RAS Mutations in Cancer Biology

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4656812openalex-extracted

inferred← citeshttps://doi.org/10.1002/cac2.12524openalex-snapshot

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK ‐positive NSCLC from a phase II study

inferred← citeshttps://doi.org/10.1002/mco2.694openalex-snapshot

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

inferred← citeshttps://doi.org/10.1007/978-3-031-93894-8_8openalex-snapshot

Molecular Mechanisms of Acquired Therapeutic Resistance to Tyrosine Kinase Targeted Therapy

inferred← citeshttps://doi.org/10.1016/j.bmc.2025.118521openalex-snapshot

Novel PROTACs with polyhedral alkanes as linkers for enhanced ALK degradation in drug-resistant NSCLC

inferred← citeshttps://doi.org/10.1016/j.chphi.2025.100984openalex-snapshot

Application of chemoinformatics and molecular simulations in lead optimization targeting A549 cell proliferation for lung cancer therapy

inferred← citeshttps://doi.org/10.1016/j.ctarc.2025.101023openalex-snapshot

Artificial intelligence-based pharmacological approach in non-small cell lung cancer in the precision medicine era

inferred← citeshttps://doi.org/10.1016/j.drup.2022.100863openalex-snapshot

Genetic alterations shaping tumor response to anti-EGFR therapies

inferred← citeshttps://doi.org/10.1016/j.jtho.2023.01.004openalex-snapshot

Response to: Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

inferred← citeshttps://doi.org/10.1016/j.jtho.2025.03.045openalex-snapshot

Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC

inferred← citeshttps://doi.org/10.1016/j.neo.2025.101133openalex-snapshot

An open-label study to determine the maximum tolerated dose of oral ESK-440 administered as a single agent in patients with advanced or metastatic solid tumors

inferred← citeshttps://doi.org/10.1038/s41392-022-01168-8openalex-snapshot

Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective

inferred← citeshttps://doi.org/10.1038/s41401-025-01511-zopenalex-snapshot

Anti-EGFR therapy can overcome acquired resistance to the third-generation ALK-tyrosine kinase inhibitor lorlatinib mediated by activation of EGFR

inferred← citeshttps://doi.org/10.1038/s41467-023-38195-0openalex-snapshot

Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma

inferred← citeshttps://doi.org/10.1038/s41598-023-34397-0openalex-snapshot

A retrospective study of postoperative targeted therapy in ALK-positive lung cancer

inferred← citeshttps://doi.org/10.1038/s44321-025-00354-9openalex-snapshot

NOTCH1 intracellular domain stabilization by MDM2 plays a major role in NSCLC response to platinum

inferred← citeshttps://doi.org/10.1080/14737140.2023.2265566openalex-snapshot

Treatment of advanced ALK-rearranged NSCLC following second-generation ALK–TKI failure

inferred← citeshttps://doi.org/10.1101/2024.04.29.591624openalex-snapshot

MDM2 stabilization of Notch intracellular domain upon DNA damage plays a major role in non-small cell lung carcinoma response to platinum chemotherapy

inferred← citeshttps://doi.org/10.1111/1759-7714.14656openalex-snapshot

MET gene amplification is a mechanism of resistance to entrectinib in ROS1 + NSCLC

inferred← citeshttps://doi.org/10.1111/1759-7714.14980openalex-snapshot

Dynamic monitoring of circulating tumor DNA to analyze genetic characteristics and resistance profile of lorlatinib in ALK positive previously treated NSCLC

inferred← citeshttps://doi.org/10.1177/17588359261480332openalex-snapshot

Lorlatinib-specific outcomes by timing of lorlatinib initiation in advanced ALK-positive non-small cell lung cancer: A retrospective cohort study

inferred← citeshttps://doi.org/10.1186/s12885-026-15916-4openalex-snapshot

Optimizing treatment and sequencing strategies for maximal survival and net health benefits in ALK-positive NSCLC: a systematic review and reconstructed individual patient data meta-analysis

inferred← citeshttps://doi.org/10.1186/s12916-022-02646-0openalex-snapshot

Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

inferred← citeshttps://doi.org/10.1200/jco-25-02822openalex-snapshot

Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, 2026.3.0

inferred← citeshttps://doi.org/10.20517/cdr.2024.25openalex-snapshot

ALK inhibitors in cancer: mechanisms of resistance and therapeutic management strategies

inferred← citeshttps://doi.org/10.21037/tlcr-23-482openalex-snapshot

Primary resistance to ALK inhibitors in KLC1/ALK-rearranged pleural metastatic lung adenocarcinoma: a case report

inferred← citeshttps://doi.org/10.2217/fon-2022-0184openalex-snapshot

Lorlatinib as a treatment for ALK-positive lung cancer

inferred← citeshttps://doi.org/10.3389/fonc.2022.1027664openalex-snapshot

Circulating tumor DNA detection in MRD assessment and diagnosis and treatment of non-small cell lung cancer

inferred← citeshttps://doi.org/10.3389/fonc.2023.1227980openalex-snapshot

Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review

inferred← citeshttps://doi.org/10.3389/fonc.2026.1779992openalex-snapshot

Acquired EGFR L858R mutation following ALK-TKI resistance in lung adenocarcinoma: a case report

inferred← citeshttps://doi.org/10.3389/fphar.2023.1125547openalex-snapshot

Recent progress in targeted therapy for non-small cell lung cancer

inferred← citeshttps://doi.org/10.3390/biomedicines12020297openalex-snapshot

Unraveling the Potential of ALK-Targeted Therapies in Non-Small Cell Lung Cancer: Comprehensive Insights and Future Directions

inferred← citeshttps://doi.org/10.3390/cancers13236003openalex-snapshot

Resistance to Targeted Agents Used to Treat Paediatric ALK-Positive ALCL

inferred← citeshttps://doi.org/10.3390/cancers14071751openalex-snapshot

Brigatinib for Pretreated, ALK-Positive, Advanced Non-Small-Cell Lung Cancers: Long-Term Follow-Up and Focus on Post-Brigatinib Lorlatinib Efficacy in the Multicenter, Real-World BrigALK2 Study

inferred← citeshttps://doi.org/10.3390/cancers14194954openalex-snapshot

Prognostic Value of Circulating Tumor DNA (ctDNA) in Oncogene-Driven NSCLC: Current Knowledge and Future Perspectives

inferred← citeshttps://doi.org/10.3390/cancers15010204openalex-snapshot

Phase II Trial of the Combination of Alectinib with Bevacizumab in Alectinib Refractory ALK-Positive Nonsquamous Non-Small-Cell Lung Cancer (NLCTG1501)

inferred← citeshttps://doi.org/10.3390/cancers16132296openalex-snapshot

Medullary Thyroid Cancer: Molecular Drivers and Immune Cellular Milieu of the Tumour Microenvironment—Implications for Systemic Treatment

inferred← citeshttps://doi.org/10.3390/cells11182871openalex-snapshot

Liquid Biopsy Analysis as a Tool for TKI-Based Treatment in Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.3390/curroncol29100618openalex-snapshot

Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer

inferred← citeshttps://doi.org/10.3390/diagnostics12030682openalex-snapshot

Multiple Genetic Alterations as Resistance Mechanism during Second-Line Lorlatinib for Advanced ALK-Rearranged Lung Adenocarcinoma: A Case Report

inferred← citeshttps://doi.org/10.3390/ijms23137037openalex-snapshot

State-of-the-Art Molecular Oncology of Lung Cancer in Taiwan

inferred← citeshttps://doi.org/10.3779/j.issn.1009-3419.2022.102.19openalex-snapshot

[Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].

inferred← citeshttps://doi.org/10.6084/m9.figshare.21622829openalex-snapshot

Additional file 1 of Conteltinib (CT-707) in patients with advanced ALK-positive non-small cell lung cancer: a multicenter, open-label, first-in-human phase 1 study

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.